Literature DB >> 26092864

Molecular mechanisms of congenital hyperinsulinism due to autosomal dominant mutations in ABCC8.

Azizun Nessa1, Qadeer H Aziz2, Alison M Thomas2, Stephen C Harmer2, Andrew Tinker2, Khalid Hussain3.   

Abstract

Congenital Hyperinsulinism (CHI) is a rare heterogeneous disease characterized by unregulated insulin secretion. Dominant mutations in ABCC8 causing medically unresponsive CHI have been reported; however, the molecular mechanisms are not clear. The molecular basis of medically unresponsive CHI due to dominant ABCC8 mutations has been studied in 10 patients, who were medically unresponsive to diazoxide (DZX), and nine of whom required a near-total pancreatectomy, and one partial pancreatectomy. DNA sequencing revealed seven dominant inactivating heterozygous missense mutations in ABCC8, including one novel and six previously reported but uncharacterized mutations. Two groups of mutations with different cellular mechanisms were characterized. Mutations in the transmembrane domain (TMD) were more responsive to channel activators such as DZX, MgADP and metabolic inhibition. The trafficking analysis has shown that nucleotide-binding domain two (NBD2) mutations are not retained in the endoplasmic reticulum (ER) and are present on the membrane. However, the TMD mutations were retained in the ER. D1506E was the most severe SUR1-NBD2 mutation. Homologous expression of D1506E revealed a near absence of KATP currents in the presence of DZX and intracellular MgADP. Heterozygous expression of D1506E showed a strong dominant-negative effect on SUR1\Kir6.2 currents. Overall, we define two groups of mutation with different cellular mechanisms. In the first group, channel complexes with mutations in NBD2 of SUR1 traffic normally but are unable to be activated by MgADP. In the second group, channels mutations in the TMD of SUR1 are retained in the ER and have variable functional impairment.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26092864     DOI: 10.1093/hmg/ddv233

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  4 in total

1.  Modeling Congenital Hyperinsulinism with ABCC8-Deficient Human Embryonic Stem Cells Generated by CRISPR/Cas9.

Authors:  Dongsheng Guo; Haikun Liu; Aynisahan Ruzi; Ge Gao; Abbas Nasir; Yanli Liu; Fan Yang; Feima Wu; Guosheng Xu; Yin-Xiong Li
Journal:  Sci Rep       Date:  2017-06-09       Impact factor: 4.379

2.  ABCC9-related Intellectual disability Myopathy Syndrome is a KATP channelopathy with loss-of-function mutations in ABCC9.

Authors:  Marie F Smeland; Conor McClenaghan; Helen I Roessler; Sanne Savelberg; Geir Åsmund Myge Hansen; Helene Hjellnes; Kjell Arne Arntzen; Kai Ivar Müller; Andreas Rosenberger Dybesland; Theresa Harter; Monica Sala-Rabanal; Chris H Emfinger; Yan Huang; Soma S Singareddy; Jamie Gunn; David F Wozniak; Attila Kovacs; Maarten Massink; Federico Tessadori; Sarah M Kamel; Jeroen Bakkers; Maria S Remedi; Marijke Van Ghelue; Colin G Nichols; Gijs van Haaften
Journal:  Nat Commun       Date:  2019-10-01       Impact factor: 14.919

Review 3.  Islet organoid as a promising model for diabetes.

Authors:  Xiaofei Zhang; Zhuo Ma; Eli Song; Tao Xu
Journal:  Protein Cell       Date:  2021-03-10       Impact factor: 14.870

4.  Loss-of-Function ABCC8 Mutations in Pulmonary Arterial Hypertension.

Authors:  Michael S Bohnen; Lijiang Ma; Na Zhu; Hongjian Qi; Conor McClenaghan; Claudia Gonzaga-Jauregui; Frederick E Dewey; John D Overton; Jeffrey G Reid; Alan R Shuldiner; Aris Baras; Kevin J Sampson; Marta Bleda; Charaka Hadinnapola; Matthias Haimel; Harm J Bogaard; Colin Church; Gerry Coghlan; Paul A Corris; Mélanie Eyries; J Simon R Gibbs; Barbara Girerd; Arjan C Houweling; Marc Humbert; Christophe Guignabert; David G Kiely; Allan Lawrie; Rob V MacKenzie Ross; Jennifer M Martin; David Montani; Andrew J Peacock; Joanna Pepke-Zaba; Florent Soubrier; Jay Suntharalingam; Mark Toshner; Carmen M Treacy; Richard C Trembath; Anton Vonk Noordegraaf; John Wharton; Martin R Wilkins; Stephen J Wort; Katherine Yates; Stefan Gräf; Nicholas W Morrell; Usha Krishnan; Erika B Rosenzweig; Yufeng Shen; Colin G Nichols; Robert S Kass; Wendy K Chung
Journal:  Circ Genom Precis Med       Date:  2018-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.